Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants.

ABSTRACT:

Background

New drugs to target different pathways in pulmonary hypertension has resulted in increased combination therapy, but details of this use in infants are not well described. In this large multicenter database study, we describe the pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants.

Methods

We identified inborn infants discharged home from a Pediatrix neonatal ICU from 1997 to 2020 exposed to inhaled nitric oxide, sildenafil, epoprostenol, or bosentan for greater than two consecutive days. We compared clinical variables and drug utilisation between infants receiving simultaneous combination and monotherapy. We reported each combination's frequency, timing, and duration and graphically represented drug use over time.

Results

SUBMITTER: Kumar KR 

PROVIDER: S-EPMC12279383 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature